Mesenchymal ovarian cancer cells promote CD8+ T cell exhaustion through the LGALS3-LAG3 axis

Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8 + T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the...

Full description

Saved in:
Bibliographic Details
Published in:NPJ systems biology and applications Vol. 9; no. 1; pp. 61 - 17
Main Authors: Yakubovich, Edward, Cook, David P., Rodriguez, Galaxia M., Vanderhyden, Barbara C.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 12.12.2023
Nature Publishing Group
Nature Portfolio
Subjects:
631/114
631/250
631/553/2711
631/67
Bioinformatics
Biomedical and Life Sciences
CD8 antigen
CD8-Positive T-Lymphocytes - metabolism
CD8-Positive T-Lymphocytes - pathology
Computational Biology/Bioinformatics
Computer Appl. in Life Sciences
Female
Galectin 3 - genetics
Galectin 3 - metabolism
Humans
Immunity
Inflammation
Life Sciences
Lymphocytes
Lymphocytes T
Mesenchyme
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Systems Biology
T-Cell Exhaustion
Tumor Microenvironment
Tumors
ISSN:2056-7189, 2056-7189
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8 + T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8 + T cells. We found CD8 + T cells express high levels of LAG3 , a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.
AbstractList Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8+ T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8+ T cells. We found CD8+ T cells express high levels of LAG3, a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.
Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8 T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8 T cells. We found CD8 T cells express high levels of LAG3, a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.
Abstract Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8+ T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8+ T cells. We found CD8+ T cells express high levels of LAG3, a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.
Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8+ T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8+ T cells. We found CD8+ T cells express high levels of LAG3, a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8+ T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8+ T cells. We found CD8+ T cells express high levels of LAG3, a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.
Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8 + T-cells in the tumor microenvironment correlates with improved survival, mesenchymal cancer cells acquire greater resistance to antitumor immunity in some cancers. We hypothesized the EMT modulates the immune response to ovarian cancer. Here we show that cancer cells from infiltrated/inflamed tumors possess more mesenchymal cells, than excluded and desert tumors. We also noted high expression of LGALS3 is associated with EMT in vivo, a finding validated with in vitro EMT models. Dissecting the cellular communications among populations in the tumor revealed that mesenchymal cancer cells in infiltrated tumors communicate through LGALS3 to LAG3 receptor expressed by CD8 + T cells. We found CD8 + T cells express high levels of LAG3 , a marker of T cell exhaustion. The results indicate that EMT in ovarian cancer cells promotes interactions between cancer cells and T cells through the LGALS3 - LAG3 axis, which could increase T cell exhaustion in infiltrated tumors, dampening antitumor immunity.
ArticleNumber 61
Author Rodriguez, Galaxia M.
Cook, David P.
Yakubovich, Edward
Vanderhyden, Barbara C.
Author_xml – sequence: 1
  givenname: Edward
  orcidid: 0000-0002-2109-1111
  surname: Yakubovich
  fullname: Yakubovich, Edward
  email: eyaku027@uottawa.ca
  organization: Department of Cellular and Molecular Medicine, University of Ottawa, Cancer Therapeutics Program, Ottawa Hospital Research Institute, Center for Infection, Immunity and Inflammation, University of Ottawa
– sequence: 2
  givenname: David P.
  surname: Cook
  fullname: Cook, David P.
  organization: Department of Cellular and Molecular Medicine, University of Ottawa, Cancer Therapeutics Program, Ottawa Hospital Research Institute
– sequence: 3
  givenname: Galaxia M.
  surname: Rodriguez
  fullname: Rodriguez, Galaxia M.
  organization: Department of Cellular and Molecular Medicine, University of Ottawa, Cancer Therapeutics Program, Ottawa Hospital Research Institute, Center for Infection, Immunity and Inflammation, University of Ottawa
– sequence: 4
  givenname: Barbara C.
  orcidid: 0000-0002-7644-7189
  surname: Vanderhyden
  fullname: Vanderhyden, Barbara C.
  organization: Department of Cellular and Molecular Medicine, University of Ottawa, Cancer Therapeutics Program, Ottawa Hospital Research Institute, Center for Infection, Immunity and Inflammation, University of Ottawa
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38086828$$D View this record in MEDLINE/PubMed
BookMark eNp9kkFvEzEQhS1UREvoH-CAVuKChBbG9q7Xe0JRgFApiAPlhmTNOrPJRhs72LtV--9xkhbaHnoay_7e89PMvGQnzjti7DWHDxyk_hgLXhaQg5A5gBQiL56xMwGlyiuu65N751N2HuMGALiSheDwgp1KDVppoc_Y7-8Uydn1zRb7zF9h6NBlFp2lkFnq-5jtgt_6gbLZZ_0-uzxcZnS9xjEOnXfZsA5-XK1TpWwxny5-ynwxncsMr7v4ij1vsY90flsn7NfXL5ezb_nix_xiNl3ktiz4kJOlomgRlaoAS6WIY1tx5E2peCVB1ZxsXXJLjS6rCtsmgVo1HGyDIISQE3Zx9F163Jhd6LYYbozHzhwufFgZDENnezJiiaWuRFHBsikKXusWFEFtkUqtlum7Cft09NqNzZaWltwQsH9g-vDFdWuz8leGQ5UazPdp3t06BP9npDiYbRf3bUNHfoxG1CBqKXQFCX37CN34MbjUqz0FtYJa6kS9uR_pX5a7KSZAHwEbfIyBWmO7AffjSQm7PkUz-50xx50xaWfMYWdMkaTikfTO_UmRPIpigt2Kwv_YT6j-Ah6U0J0
CitedBy_id crossref_primary_10_1007_s00424_024_02987_0
crossref_primary_10_1016_j_heliyon_2024_e38014
crossref_primary_10_1007_s40944_025_01009_w
crossref_primary_10_1038_s12276_024_01340_w
crossref_primary_10_1016_j_semcancer_2024_07_001
crossref_primary_10_1186_s12645_025_00340_3
crossref_primary_10_1007_s12032_025_02860_9
crossref_primary_10_3389_fimmu_2024_1412328
crossref_primary_10_1007_s10238_024_01541_7
crossref_primary_10_3390_ijms26094041
crossref_primary_10_1016_j_celrep_2025_116216
crossref_primary_10_1007_s12195_025_00857_y
crossref_primary_10_1038_s41419_024_07266_5
crossref_primary_10_1002_jcp_31491
crossref_primary_10_1038_s42003_025_08695_4
crossref_primary_10_1007_s12033_025_01473_x
Cites_doi 10.1080/2162402X.2015.1117738
10.1016/j.ygyno.2014.09.021
10.1007/s11684-018-0656-6
10.1016/j.cell.2019.05.031
10.1007/s10555-010-9226-3
10.1158/2159-8290.CD-20-0603
10.1001/jamaoncol.2017.3290
10.1038/s41586-021-04057-2
10.1155/2016/7314016
10.1186/s13059-020-02132-x
10.1158/1078-0432.CCR-21-2780
10.1158/1078-0432.CCR-20-4459
10.1016/j.cell.2021.04.048
10.1186/s13059-021-02584-9
10.18632/oncotarget.4751
10.3389/fimmu.2021.797261
10.1038/s41467-022-30755-0
10.1371/journal.pone.0046858
10.1155/2017/4015039
10.1007/s10549-013-2575-1
10.1016/j.immuni.2021.05.014
10.2147/IJGM.S332320
10.3390/ijms21197295
10.1164/rccm.201106-0965OC
10.1038/s41586-018-0206-z
10.1158/0008-5472.CAN-10-0761
10.1080/2162402X.2019.1665460
10.2196/27633
10.1080/2162402X.2018.1434467
10.1186/1471-2105-14-128
10.1371/journal.pone.0146887
10.1038/s41467-021-22800-1
10.1016/j.canlet.2020.05.012
10.1111/imr.12519
10.3727/096504018X15446984186056
10.3390/cancers13092112
10.1097/PGP.0000000000000657
10.3390/cancers11060838
10.1158/1078-0432.CCR-18-4175
10.1016/j.coi.2018.03.006
10.1097/CM9.0000000000001981
10.1016/j.ccell.2014.10.018
10.1093/nar/gkw377
10.1038/s41388-019-1124-8
10.1126/sciadv.abi7640
10.1016/j.annonc.2022.07.143
10.1093/bioinformatics/btac227
10.1038/s41467-022-28389-3
10.1016/j.ajpath.2015.12.029
10.1038/s41467-020-16066-2
10.1038/s41467-020-19408-2
10.1006/cimm.1996.0301
10.1016/j.biocel.2020.105881
10.3389/fonc.2020.00486
10.1016/j.ccell.2021.04.004
10.1186/1471-2407-13-422
10.1080/2162402X.2018.1535730
10.2147/CMAR.S171146
10.1080/2162402X.2017.1412900
10.31557/APJCP.2019.20.4.1161
10.1093/bioinformatics/btaa282
10.1158/2326-6066.CIR-14-0150
10.1186/s12943-015-0421-2
10.1038/bjc.2015.29
10.1091/mbc.e02-09-0583
10.1038/5042
10.1002/path.5155
10.1136/jitc-2021-002873
10.1016/j.trecan.2017.09.006
10.1073/pnas.1817652116
10.1038/s41587-022-01331-0
10.1158/0008-5472.CAN-08-1842
10.1002/cam4.2075
10.1172/JCI80445
10.1016/j.celrep.2020.01.076
10.3390/ijms23020833
10.1016/j.cytogfr.2021.01.005
10.1016/j.cell.2018.11.010
10.1158/0008-5472.CAN-16-3292
10.1136/jitc-2020-001650
10.1186/ar1963
10.1056/NEJMoa020177
10.1530/ERC-15-0383
10.1038/s41580-018-0080-4
10.1016/j.smim.2019.101305
10.1016/j.apsb.2020.01.005
10.1002/cpz1.90
10.1073/pnas.0903497106
10.1016/j.ccell.2021.05.005
10.1016/j.tranon.2020.100845
10.1038/s41598-021-84465-6
10.1016/j.cels.2015.12.004
10.1093/bioinformatics/btu393
10.3389/fimmu.2017.01653
10.1186/s13059-019-1874-1
10.1002/art.24574
10.1371/journal.pone.0049766
10.1126/sciimmunol.aar3451
10.3389/fphar.2022.949264
10.3389/fimmu.2019.01191
10.1038/s41392-019-0089-y
10.3389/fimmu.2020.615317
10.1101/2021.09.01.458620
10.1101/2022.02.28.482303
10.1038/s41568-022-00503-z
10.3389/fimmu.2020.598532
10.1016/j.iotech.2022.100079
10.1101/060012
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41540-023-00322-4
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic

Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2056-7189
EndPage 17
ExternalDocumentID oai_doaj_org_article_2da5872470db44198f06e09cae586d17
PMC10716312
38086828
10_1038_s41540_023_00322_4
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada)
  grantid: RGPIN 2018-06538
  funderid: https://doi.org/10.13039/501100000038
– fundername: Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada)
  grantid: RGPIN 2018-06538
GroupedDBID 0R~
5VS
7X7
8FE
8FH
8FI
AAJSJ
AASML
ABUWG
ACGFS
ADBBV
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
EBLON
EBS
FYUFA
GROUPED_DOAJ
HCIFZ
HYE
KQ8
LK8
M7P
M~E
NAO
NO~
OK1
PGMZT
PIMPY
PQQKQ
PROAC
PUEGO
RNT
RPM
SNYQT
UKHRP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FJ
8FK
AZQEC
CCPQU
DWQXO
GNUQQ
K9.
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c541t-ece44faa6670a566e1af71a1b561730691ec951ceb8577afb66786b10cba02223
IEDL.DBID DOA
ISICitedReferencesCount 22
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001127096300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2056-7189
IngestDate Tue Oct 14 19:04:22 EDT 2025
Tue Nov 04 02:06:28 EST 2025
Sun Nov 09 10:25:05 EST 2025
Sat Nov 29 14:46:42 EST 2025
Thu Sep 25 01:51:24 EDT 2025
Sat Nov 29 02:35:52 EST 2025
Tue Nov 18 21:00:11 EST 2025
Sun Aug 31 08:58:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-ece44faa6670a566e1af71a1b561730691ec951ceb8577afb66786b10cba02223
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2109-1111
0000-0002-7644-7189
OpenAccessLink https://doaj.org/article/2da5872470db44198f06e09cae586d17
PMID 38086828
PQID 2900960938
PQPubID 2041915
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_2da5872470db44198f06e09cae586d17
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10716312
proquest_miscellaneous_2902932870
proquest_journals_2900960938
pubmed_primary_38086828
crossref_citationtrail_10_1038_s41540_023_00322_4
crossref_primary_10_1038_s41540_023_00322_4
springer_journals_10_1038_s41540_023_00322_4
PublicationCentury 2000
PublicationDate 2023-12-12
PublicationDateYYYYMMDD 2023-12-12
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-12-12
  day: 12
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle NPJ systems biology and applications
PublicationTitleAbbrev npj Syst Biol Appl
PublicationTitleAlternate NPJ Syst Biol Appl
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Loret, Denys, Tummers, Berx (CR9) 2019; 11
(CR15) 2017; 3
Mettu (CR71) 2022; 28
Luk (CR80) 2020; 13
Fucikova (CR20) 2019; 25
Stuelten (CR10) 2008; 68
Slack, Mills, Mackinnon (CR68) 2021; 130
Nhokaew, Kleebkaow, Chaisuriya, Kietpeerakool (CR49) 2019; 20
Zhai (CR52) 2020; 10
MacKinnon (CR67) 2012; 185
Demotte (CR77) 2010; 70
(CR57) 2022; 40
Murakami (CR28) 2016; 186
Filippou, Karagiannis, Constantinidou, Midkine (CR36) 2020; 39
Lánczky, Győrffy (CR113) 2021; 23
Chauvin (CR74) 2015; 125
Krześlak, Lipińska (CR76) 2004; 9
McCorry, Loughrey, Longley, Lawler, Dunne (CR97) 2018; 246
Kouo (CR51) 2015; 3
Priglinger (CR83) 2016; 11
Xu, Wang, Li, Jin, Chen (CR34) 2021; 14
Cook, Vanderhyden (CR96) 2022; 8
Hafemeister, Satija (CR103) 2019; 20
Nugteren, Samsom (CR32) 2021; 59
CR40
Hou, Ji, Ji, Hicks (CR98) 2020; 21
Zhao, Wang, Xu, Liu, He (CR58) 2022; 135
Andrews, Marciscano, Drake, Vignali (CR25) 2017; 276
Zhang (CR31) 2021; 11
Kim, Lin, Geddes, Yang, Yang (CR99) 2020; 36
Bates, Mercurio (CR13) 2003; 14
Alsuliman (CR48) 2015; 14
Johnston (CR73) 2014; 26
Zhang, Weinberg (CR2) 2018; 12
Imai (CR62) 2018; 15
CR53
Huang (CR22) 2015; 6
Sahoo (CR66) 2021; 12
Hapke, Haake (CR92) 2020; 487
Liberzon (CR41) 2015; 1
Mirandola (CR85) 2014; 135
Kooi (CR45) 1996; 174
Taylor, Rudd (CR86) 2017; 8
Bachmayr-Heyda (CR16) 2013; 13
CR69
Fukumori (CR78) 2003; 63
Zvaifler (CR90) 2006; 8
Capellero (CR65) 2022; 23
CR60
Filer (CR70) 2009; 60
Trivanović (CR39) 2016; 2016
Hornburg (CR29) 2021; 39
Aptsiauri, Ruiz-Cabello, Garrido (CR46) 2018; 51
Macnair, Gupta, Claassen (CR109) 2022; 38
Desbois (CR30) 2020; 11
Kearney (CR56) 2018; 3
Woude, Van Der, Gorris, Halilovic, Figdor, Vries (CR17) 2017; 3
Chihara (CR23) 2018; 558
Chen (CR79) 2009; 106
Li (CR19) 2019; 116
Zhang (CR42) 2003; 348
Kuleshov (CR107) 2016; 44
Saxena, Jolly, Balamurugan (CR5) 2020; 13
Launonen (CR61) 2022; 13
CR110
Yang (CR12) 2010; 29
Rivera-Cruz, Shearer, Figueiredo Neto, Figueiredo (CR38) 2017; 2017
Dongre, Weinberg (CR1) 2019; 20
Choudhary, Satija (CR104) 2022; 23
Wu, Liu, Xing, Ji (CR82) 2018; 16
CR89
Xie (CR108) 2021; 1
Ricciardi (CR4) 2015; 112
Fucikova (CR21) 2021; 9
Liu (CR81) 2018; 10
MacGregor (CR37) 2019; 8
Zhang (CR87) 2018; 7
Simeonov (CR6) 2021; 39
Gu, Gu, Eils, Schlesner, Brors (CR112) 2014; 30
Stuart (CR101) 2019; 177
Hao (CR102) 2021; 184
Dimitrov (CR111) 2022; 13
Wang (CR54) 2019; 176
Rafehi (CR64) 2016; 23
Dongre (CR3) 2021; 11
CR14
Dongre (CR27) 2017; 77
Rådestad (CR63) 2018; 8
David, Hamilton, Palena (CR35) 2016; 5
Sarikonda (CR72) 2022; 33
Taki (CR8) 2021; 27
Misra, Pandey, Sze, Thanabalu (CR93) 2012; 7
He, Zhang, Chen, Li (CR55) 2019; 8
Fei (CR50) 2019; 27
Tam, Wu, Law (CR94) 2020; 10
Chen (CR106) 2013; 14
Sordo-Bahamonde (CR59) 2021; 13
Sabbatino (CR33) 2020; 21
Leem (CR84) 2020; 8
Bulle, Lim (CR91) 2020; 5
Farhad, Rolig, Redmond (CR75) 2018; 7
Whitehair, Peres, Mills (CR47) 2020; 39
Sun (CR18) 2021; 599
CR105
Tyler, Tirosh (CR95) 2021; 12
Hobson (CR11) 2013; 139
Rudd, Chanthong, Taylor (CR88) 2020; 30
CR100
Latifi (CR7) 2012; 7
Ruffo, Wu, Bruno, Workman, Vignali (CR24) 2019; 42
Bou-Tayeh, Miller (CR43) 2021; 54
Shayesteh (CR26) 1999; 21
Cook, Vanderhyden (CR44) 2020; 11
J-M Chauvin (322_CR74) 2015; 125
A Dongre (322_CR27) 2017; 77
M Taki (322_CR8) 2021; 27
D Trivanović (322_CR39) 2016; 2016
Y Zhang (322_CR2) 2018; 12
S Rafehi (322_CR64) 2016; 23
322_CR100
CH Stuelten (322_CR10) 2008; 68
N Loret (322_CR9) 2019; 11
G Leem (322_CR84) 2020; 8
E Rådestad (322_CR63) 2018; 8
A Misra (322_CR93) 2012; 7
N Chihara (322_CR23) 2018; 558
322_CR105
M Hornburg (322_CR29) 2021; 39
EY Chen (322_CR106) 2013; 14
L Yang (322_CR12) 2010; 29
M Desbois (322_CR30) 2020; 11
A Dongre (322_CR3) 2021; 11
I-M Launonen (322_CR61) 2022; 13
322_CR110
CM Rivera-Cruz (322_CR38) 2017; 2017
L Zhao (322_CR58) 2022; 135
H-M Luk (322_CR80) 2020; 13
D Dimitrov (322_CR111) 2022; 13
322_CR89
M Ricciardi (322_CR4) 2015; 112
C Hafemeister (322_CR103) 2019; 20
W Nhokaew (322_CR49) 2019; 20
N Aptsiauri (322_CR46) 2018; 51
J Wang (322_CR54) 2019; 176
L Mirandola (322_CR85) 2014; 135
K Saxena (322_CR5) 2020; 13
Y Imai (322_CR62) 2018; 15
L Shayesteh (322_CR26) 1999; 21
A Dongre (322_CR1) 2019; 20
SY Tam (322_CR94) 2020; 10
JM David (322_CR35) 2016; 5
A Alsuliman (322_CR48) 2015; 14
X He (322_CR55) 2019; 8
AC MacKinnon (322_CR67) 2012; 185
S Nugteren (322_CR32) 2021; 59
G Sarikonda (322_CR72) 2022; 33
322_CR14
DP Cook (322_CR44) 2020; 11
CS Priglinger (322_CR83) 2016; 11
A Bulle (322_CR91) 2020; 5
Z Xie (322_CR108) 2021; 1
A Bachmayr-Heyda (322_CR16) 2013; 13
Y Liu (322_CR81) 2018; 10
M Tyler (322_CR95) 2021; 12
S Sahoo (322_CR66) 2021; 12
RJ Johnston (322_CR73) 2014; 26
NB Mettu (322_CR71) 2022; 28
CE Rudd (322_CR88) 2020; 30
HL MacGregor (322_CR37) 2019; 8
S Kooi (322_CR45) 1996; 174
Ovarian Tumor Tissue Analysis (OTTA) Consortium. (322_CR15) 2017; 3
B Bou-Tayeh (322_CR43) 2021; 54
F Sabbatino (322_CR33) 2020; 21
HJ Kim (322_CR99) 2020; 36
CJ Kearney (322_CR56) 2018; 3
W Hou (322_CR98) 2020; 21
T Wu (322_CR82) 2018; 16
MV Kuleshov (322_CR107) 2016; 44
A Latifi (322_CR7) 2012; 7
W Macnair (322_CR109) 2022; 38
A Lánczky (322_CR113) 2021; 23
R-Y Huang (322_CR22) 2015; 6
LP Andrews (322_CR25) 2017; 276
E Ruffo (322_CR24) 2019; 42
M Farhad (322_CR75) 2018; 7
A Krześlak (322_CR76) 2004; 9
FDA approves anti-LAG3 checkpoint. (322_CR57) 2022; 40
J Fucikova (322_CR21) 2021; 9
RJ Slack (322_CR68) 2021; 130
H-Y Chen (322_CR79) 2009; 106
H Zhang (322_CR31) 2021; 11
H Xu (322_CR34) 2021; 14
PS Filippou (322_CR36) 2020; 39
322_CR40
C Sordo-Bahamonde (322_CR59) 2021; 13
AM McCorry (322_CR97) 2018; 246
NJ Zvaifler (322_CR90) 2006; 8
X Sun (322_CR18) 2021; 599
Z Gu (322_CR112) 2014; 30
KP Simeonov (322_CR6) 2021; 39
J-Y Zhang (322_CR87) 2018; 7
R Whitehair (322_CR47) 2020; 39
W Zhai (322_CR52) 2020; 10
RY Hapke (322_CR92) 2020; 487
S Capellero (322_CR65) 2022; 23
T Fukumori (322_CR78) 2003; 63
T Kouo (322_CR51) 2015; 3
A Taylor (322_CR86) 2017; 8
322_CR53
A Liberzon (322_CR41) 2015; 1
L Zhang (322_CR42) 2003; 348
J Fucikova (322_CR20) 2019; 25
A Filer (322_CR70) 2009; 60
T Stuart (322_CR101) 2019; 177
N Demotte (322_CR77) 2010; 70
RC Bates (322_CR13) 2003; 14
J Hobson (322_CR11) 2013; 139
X Li (322_CR19) 2019; 116
R Murakami (322_CR28) 2016; 186
S Choudhary (322_CR104) 2022; 23
Z Fei (322_CR50) 2019; 27
322_CR60
Y Hao (322_CR102) 2021; 184
LL Woude (322_CR17) 2017; 3
DP Cook (322_CR96) 2022; 8
322_CR69
References_xml – volume: 5
  start-page: e1117738
  year: 2016
  ident: CR35
  article-title: MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2015.1117738
– volume: 135
  start-page: 573
  year: 2014
  end-page: 579
  ident: CR85
  article-title: Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2014.09.021
– volume: 12
  start-page: 361
  year: 2018
  end-page: 373
  ident: CR2
  article-title: Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
  publication-title: Front. Med.
  doi: 10.1007/s11684-018-0656-6
– volume: 177
  start-page: 1888
  year: 2019
  end-page: 1902.e21
  ident: CR101
  article-title: Comprehensive integration of single-cell data
  publication-title: Cell
  doi: 10.1016/j.cell.2019.05.031
– volume: 29
  start-page: 263
  year: 2010
  end-page: 271
  ident: CR12
  article-title: TGFβ and cancer metastasis: an inflammation link
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-010-9226-3
– volume: 11
  start-page: 1286
  year: 2021
  end-page: 1305
  ident: CR3
  article-title: Direct and indirect regulators of epithelial–mesenchymal transition–mediated immunosuppression in breast carcinomas
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-0603
– volume: 3
  start-page: e173290
  year: 2017
  ident: CR15
  article-title: Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2017.3290
– volume: 599
  start-page: 673
  year: 2021
  end-page: 678
  ident: CR18
  article-title: Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion
  publication-title: Nature
  doi: 10.1038/s41586-021-04057-2
– volume: 2016
  start-page: 7314016
  year: 2016
  ident: CR39
  article-title: The roles of mesenchymal stromal/stem cells in tumor microenvironment associated with inflammation
  publication-title: Mediators Inflamm.
  doi: 10.1155/2016/7314016
– volume: 21
  year: 2020
  ident: CR98
  article-title: A systematic evaluation of single-cell RNA-sequencing imputation methods
  publication-title: Genome Biol.
  doi: 10.1186/s13059-020-02132-x
– volume: 28
  start-page: 882
  year: 2022
  end-page: 892
  ident: CR71
  article-title: A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-2780
– ident: CR60
– volume: 27
  start-page: 4669
  year: 2021
  end-page: 4679
  ident: CR8
  article-title: Tumor immune microenvironment during epithelial–mesenchymal transition
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-4459
– volume: 184
  start-page: 3573
  year: 2021
  end-page: 3587.e29
  ident: CR102
  article-title: Integrated analysis of multimodal single-cell data
  publication-title: Cell
  doi: 10.1016/j.cell.2021.04.048
– volume: 23
  year: 2022
  ident: CR104
  article-title: Comparison and evaluation of statistical error models for scRNA-seq
  publication-title: Genome Biol.
  doi: 10.1186/s13059-021-02584-9
– volume: 6
  start-page: 27359
  year: 2015
  end-page: 27377
  ident: CR22
  article-title: LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4751
– volume: 12
  start-page: 797261
  year: 2021
  ident: CR66
  article-title: Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.797261
– volume: 13
  year: 2022
  ident: CR111
  article-title: Comparison of methods and resources for cell-cell communication inference from single-cell RNA-Seq data
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-30755-0
– ident: CR100
– volume: 7
  start-page: e46858
  year: 2012
  ident: CR7
  article-title: Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0046858
– volume: 2017
  start-page: 4015039
  year: 2017
  ident: CR38
  article-title: The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche
  publication-title: Stem Cells Int.
  doi: 10.1155/2017/4015039
– ident: CR89
– volume: 139
  start-page: 391
  year: 2013
  end-page: 401
  ident: CR11
  article-title: Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-013-2575-1
– volume: 54
  start-page: 1107
  year: 2021
  end-page: 1109
  ident: CR43
  article-title: Ovarian tumors orchestrate distinct cellular compositions
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.05.014
– volume: 14
  start-page: 5537
  year: 2021
  ident: CR34
  article-title: The immune-related Gene ELF3 is a novel biomarker for the prognosis of ovarian cancer
  publication-title: Int. J. Gen. Med.
  doi: 10.2147/IJGM.S332320
– volume: 21
  start-page: 7295
  year: 2020
  ident: CR33
  article-title: Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21197295
– volume: 185
  start-page: 537
  year: 2012
  end-page: 546
  ident: CR67
  article-title: Regulation of transforming growth Factor-β1–driven Lung Fibrosis by Galectin-3
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201106-0965OC
– volume: 558
  start-page: 454
  year: 2018
  end-page: 459
  ident: CR23
  article-title: Induction and transcriptional regulation of the co-inhibitory gene module in T cells
  publication-title: Nature
  doi: 10.1038/s41586-018-0206-z
– volume: 70
  start-page: 7476
  year: 2010
  end-page: 7488
  ident: CR77
  article-title: A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-0761
– volume: 16
  start-page: 1968
  year: 2018
  end-page: 1974
  ident: CR82
  article-title: Baicalin and puerarin reverse epithelial-mesenchymal transition via the TGF-β1/Smad3 pathway in vitro
  publication-title: Exp. Ther. Med.
– volume: 8
  start-page: e1665460
  year: 2019
  ident: CR37
  article-title: Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2019.1665460
– volume: 23
  start-page: e27633
  year: 2021
  ident: CR113
  article-title: Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): development and implementation
  publication-title: J. Med. Internet Res.
  doi: 10.2196/27633
– volume: 7
  start-page: e1434467
  year: 2018
  ident: CR75
  article-title: The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2018.1434467
– ident: CR69
– volume: 14
  year: 2013
  ident: CR106
  article-title: Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
  publication-title: BMC Bioinforma.
  doi: 10.1186/1471-2105-14-128
– volume: 11
  start-page: e0146887
  year: 2016
  ident: CR83
  article-title: Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased β1,6-N-Glycosylation and Increased Susceptibility to Galectin-3 Binding
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0146887
– volume: 12
  year: 2021
  ident: CR95
  article-title: Decoupling epithelial-mesenchymal transitions from stromal profiles by integrative expression analysis
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22800-1
– volume: 487
  start-page: 10
  year: 2020
  end-page: 20
  ident: CR92
  article-title: Hypoxia-induced epithelial to mesenchymal transition in cancer
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.05.012
– volume: 276
  start-page: 80
  year: 2017
  end-page: 96
  ident: CR25
  article-title: LAG3 (CD223) as a cancer immunotherapy target
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12519
– volume: 27
  start-page: 801
  year: 2019
  end-page: 807
  ident: CR50
  article-title: PD-L1 induces epithelial–mesenchymal transition in nasopharyngeal carcinoma cells through activation of the PI3K/AKT pathway
  publication-title: Oncol. Res.
  doi: 10.3727/096504018X15446984186056
– volume: 13
  start-page: 2112
  year: 2021
  ident: CR59
  article-title: LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
  publication-title: Cancers
  doi: 10.3390/cancers13092112
– volume: 39
  start-page: 558
  year: 2020
  end-page: 566
  ident: CR47
  article-title: Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status
  publication-title: Int. J. Gynecol. Pathol.
  doi: 10.1097/PGP.0000000000000657
– volume: 11
  start-page: 838
  year: 2019
  ident: CR9
  article-title: The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance
  publication-title: Cancers
  doi: 10.3390/cancers11060838
– volume: 25
  start-page: 4820
  year: 2019
  end-page: 4831
  ident: CR20
  article-title: TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-4175
– volume: 51
  start-page: 123
  year: 2018
  end-page: 132
  ident: CR46
  article-title: The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2018.03.006
– volume: 135
  start-page: 1203
  year: 2022
  end-page: 1212
  ident: CR58
  article-title: Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
  publication-title: Chin. Med. J.
  doi: 10.1097/CM9.0000000000001981
– volume: 26
  start-page: 923
  year: 2014
  end-page: 937
  ident: CR73
  article-title: The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.10.018
– volume: 44
  start-page: W90
  year: 2016
  end-page: W97
  ident: CR107
  article-title: Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkw377
– volume: 39
  start-page: 2040
  year: 2020
  end-page: 2054
  ident: CR36
  article-title: growth factor: a key player in cancer progression and a promising therapeutic target
  publication-title: Oncogene
  doi: 10.1038/s41388-019-1124-8
– volume: 8
  start-page: eabi7640
  year: 2022
  ident: CR96
  article-title: Transcriptional census of epithelial-mesenchymal plasticity in cancer
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abi7640
– volume: 33
  start-page: S589
  year: 2022
  ident: CR72
  article-title: 111P Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.07.143
– volume: 38
  start-page: i290
  year: 2022
  end-page: i298
  ident: CR109
  article-title: psupertime: supervised pseudotime analysis for time-series single-cell RNA-seq data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btac227
– volume: 13
  year: 2022
  ident: CR61
  article-title: Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28389-3
– volume: 186
  start-page: 1103
  year: 2016
  end-page: 1113
  ident: CR28
  article-title: Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2015.12.029
– volume: 13
  start-page: 1197
  year: 2020
  end-page: 1205
  ident: CR80
  article-title: Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 11
  year: 2020
  ident: CR44
  article-title: Context specificity of the EMT transcriptional response
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-16066-2
– volume: 11
  year: 2020
  ident: CR30
  article-title: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19408-2
– volume: 174
  start-page: 116
  year: 1996
  end-page: 128
  ident: CR45
  article-title: HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2
  publication-title: Cell. Immunol.
  doi: 10.1006/cimm.1996.0301
– volume: 130
  start-page: 105881
  year: 2021
  ident: CR68
  article-title: The therapeutic potential of galectin-3 inhibition in fibrotic disease
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2020.105881
– volume: 10
  start-page: 486
  year: 2020
  ident: CR94
  article-title: Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and Beyond
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.00486
– volume: 39
  start-page: 928
  year: 2021
  end-page: 944.e6
  ident: CR29
  article-title: Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.04.004
– volume: 13
  year: 2013
  ident: CR16
  article-title: Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-13-422
– volume: 8
  start-page: e1535730
  year: 2018
  ident: CR63
  article-title: Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1535730
– volume: 10
  start-page: 3963
  year: 2018
  end-page: 3971
  ident: CR81
  article-title: Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S171146
– volume: 7
  start-page: e1412900
  year: 2018
  ident: CR87
  article-title: Modulation of CD8+ memory stem T cell activity and glycogen synthase kinase 3β inhibition enhances anti-tumoral immunity in gastric cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1412900
– volume: 20
  start-page: 1161
  year: 2019
  end-page: 1169
  ident: CR49
  article-title: Programmed Death Ligand 1 (PD-L1) expression in epithelial ovarian cancer: a comparison of type i and type ii tumors
  publication-title: Asian Pac. J. Cancer Prev. APJCP
  doi: 10.31557/APJCP.2019.20.4.1161
– volume: 36
  start-page: 4137
  year: 2020
  end-page: 4143
  ident: CR99
  article-title: CiteFuse enables multi-modal analysis of CITE-seq data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btaa282
– volume: 3
  start-page: 412
  year: 2015
  end-page: 423
  ident: CR51
  article-title: Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0150
– volume: 14
  year: 2015
  ident: CR48
  article-title: Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-015-0421-2
– volume: 112
  start-page: 1067
  year: 2015
  end-page: 1075
  ident: CR4
  article-title: Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.29
– volume: 14
  start-page: 1790
  year: 2003
  end-page: 1800
  ident: CR13
  article-title: Tumor Necrosis Factor-α stimulates the Epithelial-to-mesenchymal transition of human colonic organoids
  publication-title: Mol. Biol. Cell
  doi: 10.1091/mbc.e02-09-0583
– volume: 21
  start-page: 99
  year: 1999
  end-page: 102
  ident: CR26
  article-title: PIK3CA is implicated as an oncogene in ovarian cancer
  publication-title: Nat. Genet.
  doi: 10.1038/5042
– volume: 246
  start-page: 422
  year: 2018
  end-page: 426
  ident: CR97
  article-title: Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition
  publication-title: J. Pathol.
  doi: 10.1002/path.5155
– ident: CR105
– volume: 9
  start-page: e002873
  year: 2021
  ident: CR21
  article-title: Immunological configuration of ovarian carcinoma: features and impact on disease outcome
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-002873
– volume: 3
  start-page: 797
  year: 2017
  end-page: 808
  ident: CR17
  article-title: Migrating into the Tumor: a Roadmap for T Cells.
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2017.09.006
– volume: 116
  start-page: 3678
  year: 2019
  end-page: 3687
  ident: CR19
  article-title: Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1817652116
– volume: 40
  start-page: 625
  year: 2022
  end-page: 625
  ident: CR57
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-022-01331-0
– volume: 68
  start-page: 7278
  year: 2008
  end-page: 7282
  ident: CR10
  article-title: Acute wounds accelerate tumorigenesis by a T-Cell dependent mechanism
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-1842
– volume: 8
  start-page: 2031
  year: 2019
  end-page: 2040
  ident: CR55
  article-title: Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma
  publication-title: Cancer Med.
  doi: 10.1002/cam4.2075
– ident: CR14
– ident: CR53
– volume: 125
  start-page: 2046
  year: 2015
  end-page: 2058
  ident: CR74
  article-title: TIGIT and PD-1 impair tumor antigen-specific CD8 T cells in melanoma patients
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI80445
– volume: 30
  start-page: 2075
  year: 2020
  end-page: 2082.e4
  ident: CR88
  article-title: Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory Co-receptor LAG-3 for enhanced anti-tumor immunity
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2020.01.076
– volume: 23
  start-page: 833
  year: 2022
  ident: CR65
  article-title: Ovarian cancer cells in ascites form aggregates that display a hybrid epithelial-mesenchymal phenotype and allows survival and proliferation of metastasizing cells
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23020833
– volume: 59
  start-page: 22
  year: 2021
  end-page: 35
  ident: CR32
  article-title: Secretory Leukocyte Protease Inhibitor (SLPI) in mucosal tissues: protects against inflammation, but promotes cancer
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2021.01.005
– volume: 176
  start-page: 334
  year: 2019
  end-page: 347.e12
  ident: CR54
  article-title: Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.010
– volume: 15
  start-page: 6457
  year: 2018
  end-page: 6468
  ident: CR62
  article-title: Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma
  publication-title: Oncol. Lett.
– volume: 77
  start-page: 3982
  year: 2017
  end-page: 3989
  ident: CR27
  article-title: Epithelial-to-mesenchymal Transition contributes to Immunosuppression in Breast Carcinomas
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3292
– ident: CR40
– volume: 8
  start-page: e001650
  year: 2020
  ident: CR84
  article-title: 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001650
– volume: 8
  start-page: 210
  year: 2006
  ident: CR90
  article-title: Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar1963
– volume: 348
  start-page: 203
  year: 2003
  end-page: 213
  ident: CR42
  article-title: Intratumoral T Cells, recurrence, and survival in epithelial ovarian cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa020177
– volume: 63
  start-page: 8302
  year: 2003
  end-page: 8311
  ident: CR78
  article-title: CD29 and CD7 Mediate Galectin-3-Induced Type II T-Cell Apoptosis
  publication-title: Cancer Res.
– volume: 23
  start-page: 147
  year: 2016
  end-page: 159
  ident: CR64
  article-title: TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids
  publication-title: Endocr. Relat. Cancer
  doi: 10.1530/ERC-15-0383
– volume: 20
  start-page: 69
  year: 2019
  end-page: 84
  ident: CR1
  article-title: New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-018-0080-4
– volume: 5
  start-page: 1
  year: 2020
  end-page: 12
  ident: CR91
  article-title: Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
  publication-title: Signal Transduct. Target. Ther.
– volume: 42
  start-page: 101305
  year: 2019
  ident: CR24
  article-title: Lymphocyte-Activation Gene 3 (LAG3): the next immune checkpoint receptor
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2019.101305
– volume: 10
  start-page: 1047
  year: 2020
  end-page: 1060
  ident: CR52
  article-title: A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2020.01.005
– volume: 1
  start-page: e90
  year: 2021
  ident: CR108
  article-title: Gene set knowledge discovery with enrichr
  publication-title: Curr. Protoc.
  doi: 10.1002/cpz1.90
– volume: 106
  start-page: 14496
  year: 2009
  end-page: 14501
  ident: CR79
  article-title: Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0903497106
– volume: 39
  start-page: 1150
  year: 2021
  end-page: 1162.e9
  ident: CR6
  article-title: Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.05.005
– volume: 13
  start-page: 100845
  year: 2020
  ident: CR5
  article-title: Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2020.100845
– volume: 11
  year: 2021
  ident: CR31
  article-title: B2M overexpression correlates with malignancy and immune signatures in human gliomas
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-84465-6
– volume: 1
  start-page: 417
  year: 2015
  end-page: 425
  ident: CR41
  article-title: The Molecular Signatures Database (MSigDB) hallmark gene set collection
  publication-title: Cell Syst.
  doi: 10.1016/j.cels.2015.12.004
– volume: 30
  start-page: 2811
  year: 2014
  end-page: 2812
  ident: CR112
  article-title: circlize implements and enhances circular visualization in R
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btu393
– volume: 8
  start-page: 1653
  year: 2017
  ident: CR86
  article-title: Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.01653
– ident: CR110
– volume: 9
  start-page: 305
  year: 2004
  end-page: 328
  ident: CR76
  article-title: Galectin-3 as a multifunctional protein
  publication-title: Cell. Mol. Biol. Lett.
– volume: 20
  year: 2019
  ident: CR103
  article-title: Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression
  publication-title: Genome Biol.
  doi: 10.1186/s13059-019-1874-1
– volume: 60
  start-page: 1604
  year: 2009
  end-page: 1614
  ident: CR70
  article-title: Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.24574
– volume: 7
  start-page: e49766
  year: 2012
  ident: CR93
  article-title: Hypoxia activated EGFR signaling induces Epithelial to Mesenchymal Transition (EMT)
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0049766
– volume: 3
  start-page: eaar3451
  year: 2018
  ident: CR56
  article-title: Tumor immune evasion arises through loss of TNF sensitivity
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.aar3451
– volume: 3
  start-page: e173290
  year: 2017
  ident: 322_CR15
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2017.3290
– volume: 8
  start-page: eabi7640
  year: 2022
  ident: 322_CR96
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abi7640
– volume: 8
  start-page: 210
  year: 2006
  ident: 322_CR90
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar1963
– volume: 51
  start-page: 123
  year: 2018
  ident: 322_CR46
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2018.03.006
– volume: 7
  start-page: e49766
  year: 2012
  ident: 322_CR93
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0049766
– volume: 11
  start-page: 1286
  year: 2021
  ident: 322_CR3
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-0603
– volume: 27
  start-page: 4669
  year: 2021
  ident: 322_CR8
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-4459
– volume: 186
  start-page: 1103
  year: 2016
  ident: 322_CR28
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2015.12.029
– ident: 322_CR69
  doi: 10.3389/fphar.2022.949264
– volume: 1
  start-page: e90
  year: 2021
  ident: 322_CR108
  publication-title: Curr. Protoc.
  doi: 10.1002/cpz1.90
– volume: 276
  start-page: 80
  year: 2017
  ident: 322_CR25
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12519
– volume: 3
  start-page: 412
  year: 2015
  ident: 322_CR51
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0150
– volume: 125
  start-page: 2046
  year: 2015
  ident: 322_CR74
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI80445
– volume: 7
  start-page: e1434467
  year: 2018
  ident: 322_CR75
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2018.1434467
– volume: 12
  start-page: 797261
  year: 2021
  ident: 322_CR66
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.797261
– volume: 135
  start-page: 1203
  year: 2022
  ident: 322_CR58
  publication-title: Chin. Med. J.
  doi: 10.1097/CM9.0000000000001981
– volume: 177
  start-page: 1888
  year: 2019
  ident: 322_CR101
  publication-title: Cell
  doi: 10.1016/j.cell.2019.05.031
– volume: 15
  start-page: 6457
  year: 2018
  ident: 322_CR62
  publication-title: Oncol. Lett.
– volume: 27
  start-page: 801
  year: 2019
  ident: 322_CR50
  publication-title: Oncol. Res.
  doi: 10.3727/096504018X15446984186056
– volume: 184
  start-page: 3573
  year: 2021
  ident: 322_CR102
  publication-title: Cell
  doi: 10.1016/j.cell.2021.04.048
– volume: 20
  start-page: 69
  year: 2019
  ident: 322_CR1
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-018-0080-4
– volume: 3
  start-page: 797
  year: 2017
  ident: 322_CR17
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2017.09.006
– volume: 8
  start-page: e1535730
  year: 2018
  ident: 322_CR63
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1535730
– volume: 7
  start-page: e46858
  year: 2012
  ident: 322_CR7
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0046858
– volume: 13
  year: 2013
  ident: 322_CR16
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-13-422
– volume: 20
  start-page: 1161
  year: 2019
  ident: 322_CR49
  publication-title: Asian Pac. J. Cancer Prev. APJCP
  doi: 10.31557/APJCP.2019.20.4.1161
– volume: 185
  start-page: 537
  year: 2012
  ident: 322_CR67
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201106-0965OC
– volume: 5
  start-page: e1117738
  year: 2016
  ident: 322_CR35
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2015.1117738
– volume: 13
  start-page: 1197
  year: 2020
  ident: 322_CR80
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 11
  start-page: e0146887
  year: 2016
  ident: 322_CR83
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0146887
– volume: 139
  start-page: 391
  year: 2013
  ident: 322_CR11
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-013-2575-1
– volume: 174
  start-page: 116
  year: 1996
  ident: 322_CR45
  publication-title: Cell. Immunol.
  doi: 10.1006/cimm.1996.0301
– volume: 39
  start-page: 2040
  year: 2020
  ident: 322_CR36
  publication-title: Oncogene
  doi: 10.1038/s41388-019-1124-8
– volume: 8
  start-page: e1665460
  year: 2019
  ident: 322_CR37
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2019.1665460
– volume: 60
  start-page: 1604
  year: 2009
  ident: 322_CR70
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.24574
– volume: 28
  start-page: 882
  year: 2022
  ident: 322_CR71
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-2780
– volume: 1
  start-page: 417
  year: 2015
  ident: 322_CR41
  publication-title: Cell Syst.
  doi: 10.1016/j.cels.2015.12.004
– volume: 348
  start-page: 203
  year: 2003
  ident: 322_CR42
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa020177
– volume: 54
  start-page: 1107
  year: 2021
  ident: 322_CR43
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.05.014
– volume: 599
  start-page: 673
  year: 2021
  ident: 322_CR18
  publication-title: Nature
  doi: 10.1038/s41586-021-04057-2
– volume: 7
  start-page: e1412900
  year: 2018
  ident: 322_CR87
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1412900
– volume: 112
  start-page: 1067
  year: 2015
  ident: 322_CR4
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.29
– volume: 558
  start-page: 454
  year: 2018
  ident: 322_CR23
  publication-title: Nature
  doi: 10.1038/s41586-018-0206-z
– volume: 12
  start-page: 361
  year: 2018
  ident: 322_CR2
  publication-title: Front. Med.
  doi: 10.1007/s11684-018-0656-6
– ident: 322_CR40
  doi: 10.3389/fimmu.2019.01191
– volume: 21
  start-page: 99
  year: 1999
  ident: 322_CR26
  publication-title: Nat. Genet.
  doi: 10.1038/5042
– volume: 11
  year: 2021
  ident: 322_CR31
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-84465-6
– volume: 14
  start-page: 1790
  year: 2003
  ident: 322_CR13
  publication-title: Mol. Biol. Cell
  doi: 10.1091/mbc.e02-09-0583
– volume: 6
  start-page: 27359
  year: 2015
  ident: 322_CR22
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4751
– volume: 9
  start-page: e002873
  year: 2021
  ident: 322_CR21
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-002873
– volume: 11
  year: 2020
  ident: 322_CR44
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-16066-2
– volume: 5
  start-page: 1
  year: 2020
  ident: 322_CR91
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-019-0089-y
– ident: 322_CR53
  doi: 10.3389/fimmu.2020.615317
– volume: 39
  start-page: 928
  year: 2021
  ident: 322_CR29
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.04.004
– volume: 16
  start-page: 1968
  year: 2018
  ident: 322_CR82
  publication-title: Exp. Ther. Med.
– volume: 14
  year: 2015
  ident: 322_CR48
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-015-0421-2
– volume: 26
  start-page: 923
  year: 2014
  ident: 322_CR73
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.10.018
– ident: 322_CR110
  doi: 10.1101/2021.09.01.458620
– volume: 30
  start-page: 2811
  year: 2014
  ident: 322_CR112
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btu393
– volume: 11
  start-page: 838
  year: 2019
  ident: 322_CR9
  publication-title: Cancers
  doi: 10.3390/cancers11060838
– volume: 106
  start-page: 14496
  year: 2009
  ident: 322_CR79
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0903497106
– volume: 13
  start-page: 2112
  year: 2021
  ident: 322_CR59
  publication-title: Cancers
  doi: 10.3390/cancers13092112
– volume: 30
  start-page: 2075
  year: 2020
  ident: 322_CR88
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2020.01.076
– volume: 176
  start-page: 334
  year: 2019
  ident: 322_CR54
  publication-title: Cell
  doi: 10.1016/j.cell.2018.11.010
– volume: 8
  start-page: 2031
  year: 2019
  ident: 322_CR55
  publication-title: Cancer Med.
  doi: 10.1002/cam4.2075
– volume: 70
  start-page: 7476
  year: 2010
  ident: 322_CR77
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-0761
– volume: 68
  start-page: 7278
  year: 2008
  ident: 322_CR10
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-1842
– volume: 135
  start-page: 573
  year: 2014
  ident: 322_CR85
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2014.09.021
– volume: 23
  start-page: e27633
  year: 2021
  ident: 322_CR113
  publication-title: J. Med. Internet Res.
  doi: 10.2196/27633
– volume: 39
  start-page: 1150
  year: 2021
  ident: 322_CR6
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.05.005
– volume: 13
  year: 2022
  ident: 322_CR111
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-30755-0
– volume: 63
  start-page: 8302
  year: 2003
  ident: 322_CR78
  publication-title: Cancer Res.
– volume: 20
  year: 2019
  ident: 322_CR103
  publication-title: Genome Biol.
  doi: 10.1186/s13059-019-1874-1
– volume: 10
  start-page: 3963
  year: 2018
  ident: 322_CR81
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S171146
– volume: 8
  start-page: e001650
  year: 2020
  ident: 322_CR84
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001650
– volume: 29
  start-page: 263
  year: 2010
  ident: 322_CR12
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-010-9226-3
– ident: 322_CR100
  doi: 10.1101/2022.02.28.482303
– ident: 322_CR14
  doi: 10.1038/s41568-022-00503-z
– volume: 40
  start-page: 625
  year: 2022
  ident: 322_CR57
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-022-01331-0
– ident: 322_CR89
  doi: 10.3389/fimmu.2020.598532
– volume: 13
  start-page: 100845
  year: 2020
  ident: 322_CR5
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2020.100845
– volume: 23
  year: 2022
  ident: 322_CR104
  publication-title: Genome Biol.
  doi: 10.1186/s13059-021-02584-9
– volume: 33
  start-page: S589
  year: 2022
  ident: 322_CR72
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.07.143
– volume: 14
  year: 2013
  ident: 322_CR106
  publication-title: BMC Bioinforma.
  doi: 10.1186/1471-2105-14-128
– volume: 14
  start-page: 5537
  year: 2021
  ident: 322_CR34
  publication-title: Int. J. Gen. Med.
  doi: 10.2147/IJGM.S332320
– volume: 12
  year: 2021
  ident: 322_CR95
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22800-1
– volume: 3
  start-page: eaar3451
  year: 2018
  ident: 322_CR56
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.aar3451
– volume: 44
  start-page: W90
  year: 2016
  ident: 322_CR107
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkw377
– volume: 10
  start-page: 1047
  year: 2020
  ident: 322_CR52
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2020.01.005
– volume: 38
  start-page: i290
  year: 2022
  ident: 322_CR109
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btac227
– volume: 10
  start-page: 486
  year: 2020
  ident: 322_CR94
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.00486
– volume: 2016
  start-page: 7314016
  year: 2016
  ident: 322_CR39
  publication-title: Mediators Inflamm.
  doi: 10.1155/2016/7314016
– volume: 11
  year: 2020
  ident: 322_CR30
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19408-2
– ident: 322_CR60
  doi: 10.1016/j.iotech.2022.100079
– volume: 23
  start-page: 833
  year: 2022
  ident: 322_CR65
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23020833
– volume: 25
  start-page: 4820
  year: 2019
  ident: 322_CR20
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-4175
– volume: 21
  start-page: 7295
  year: 2020
  ident: 322_CR33
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21197295
– volume: 130
  start-page: 105881
  year: 2021
  ident: 322_CR68
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2020.105881
– volume: 2017
  start-page: 4015039
  year: 2017
  ident: 322_CR38
  publication-title: Stem Cells Int.
  doi: 10.1155/2017/4015039
– volume: 42
  start-page: 101305
  year: 2019
  ident: 322_CR24
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2019.101305
– volume: 39
  start-page: 558
  year: 2020
  ident: 322_CR47
  publication-title: Int. J. Gynecol. Pathol.
  doi: 10.1097/PGP.0000000000000657
– volume: 36
  start-page: 4137
  year: 2020
  ident: 322_CR99
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btaa282
– volume: 13
  year: 2022
  ident: 322_CR61
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28389-3
– ident: 322_CR105
  doi: 10.1101/060012
– volume: 246
  start-page: 422
  year: 2018
  ident: 322_CR97
  publication-title: J. Pathol.
  doi: 10.1002/path.5155
– volume: 59
  start-page: 22
  year: 2021
  ident: 322_CR32
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2021.01.005
– volume: 23
  start-page: 147
  year: 2016
  ident: 322_CR64
  publication-title: Endocr. Relat. Cancer
  doi: 10.1530/ERC-15-0383
– volume: 77
  start-page: 3982
  year: 2017
  ident: 322_CR27
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3292
– volume: 9
  start-page: 305
  year: 2004
  ident: 322_CR76
  publication-title: Cell. Mol. Biol. Lett.
– volume: 8
  start-page: 1653
  year: 2017
  ident: 322_CR86
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.01653
– volume: 487
  start-page: 10
  year: 2020
  ident: 322_CR92
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.05.012
– volume: 116
  start-page: 3678
  year: 2019
  ident: 322_CR19
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1817652116
– volume: 21
  year: 2020
  ident: 322_CR98
  publication-title: Genome Biol.
  doi: 10.1186/s13059-020-02132-x
SSID ssj0001634210
Score 2.365549
Snippet Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8 + T-cells in the tumor microenvironment...
Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8 T-cells in the tumor microenvironment...
Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8+ T-cells in the tumor microenvironment...
Abstract Cancer cells often metastasize by undergoing an epithelial-mesenchymal transition (EMT). Although abundance of CD8+ T-cells in the tumor...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 61
SubjectTerms 631/114
631/250
631/553/2711
631/67
Bioinformatics
Biomedical and Life Sciences
CD8 antigen
CD8-Positive T-Lymphocytes - metabolism
CD8-Positive T-Lymphocytes - pathology
Computational Biology/Bioinformatics
Computer Appl. in Life Sciences
Female
Galectin 3 - genetics
Galectin 3 - metabolism
Humans
Immunity
Inflammation
Life Sciences
Lymphocytes
Lymphocytes T
Mesenchyme
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Systems Biology
T-Cell Exhaustion
Tumor Microenvironment
Tumors
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSF8ia0ICNxK1Hj2HGcE1oKLYelqkSRekCybMdhV4Jk2Wyr9t8z43h3tTx64RQpmUhOvhnPN_Z4hpDXmQA35aRIiyxzqZDcpxa8TspUZYGd56WqA9Lj8vhYnZ1VJ3HBrY9plcs5MUzUdedwjXw_r4bqaFy9nf1MsWsU7q7GFho3yS2skpCH1L2T9RqL5AJCmnhWJuNqvwd_hfmMOU9BnSEOExv-KJTt_xvX_DNl8rd90-CODrf_90Puk3uRiNLRoDkPyA3fPiR3htaUV4_I1094LMlNrn6AUHcBEbVpqUMVmVNc7O_pLCTyeXrwXu3R03CT-ssJ1hECrGlsAARXT8dHo_Fnno5HR5yay2n_mHw5_HB68DGNnRhSVwi2SL3zQjTGSFlmBgigZ6YpmWEW2BdMEbJi3gFVc96qoixNY0FQScsyZw1GlPwJ2Wq71j8jFOaAWllppeMlkMUC6ApvsMy8VR7JTELYEg_tYply7JbxXYftcq70gKEGDHXAUIuE7K3emQ1FOq6VfocwrySxwHa40c2_6WivOq9NocpclFltgTFWqsmkzypnfKFkjcPcXaKro9X3eg1tQl6tHoO9IgSm9d15kAGGhdvLCXk66NRqJFxBgAkhcELUhrZtDHXzSTudhJrgEMWDtrM8IW-Wirke17__xfPrP2OH3M3RVhg2wNklW4v5uX9BbruLxbSfvwzG9gthuyut
  priority: 102
  providerName: ProQuest
Title Mesenchymal ovarian cancer cells promote CD8+ T cell exhaustion through the LGALS3-LAG3 axis
URI https://link.springer.com/article/10.1038/s41540-023-00322-4
https://www.ncbi.nlm.nih.gov/pubmed/38086828
https://www.proquest.com/docview/2900960938
https://www.proquest.com/docview/2902932870
https://pubmed.ncbi.nlm.nih.gov/PMC10716312
https://doaj.org/article/2da5872470db44198f06e09cae586d17
Volume 9
WOSCitedRecordID wos001127096300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2056-7189
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001634210
  issn: 2056-7189
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2056-7189
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001634210
  issn: 2056-7189
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swED-2boO9jH123rqgwd46U8uSJfkx7dJukIawdZDBwEiyTAKbU-K0tC_923uSnazZ58tebJDOIHR33O-s0-8A3iQcw5QVPM6SxMZcMBcbjDoxVblBdJ5KVQZND-VopCaTfHyj1ZevCWvpgduN20tLnSmZcpmUBkN3rqpEuCS32mVKlDTcI09kfiOZCn9XBOOYzHS3ZBKm9hqMVL6SMWUxGjJmYHwjEgXC_t-hzF-LJX86MQ2B6PAhPOgQJOm3K38Et1z9GO61PSUvn8DXY3-fyE4vv6PQ_BxTYV0T63W7IP4vfUNOQwWeIwfv1C45CYPEXUw9ARAqiXSde_DtyPCoP_zE4mH_iBF9MWuewufDwcnB-7hroRDbjNNl7KzjvNJaCJloRG6O6kpSTQ3CJvRtkVNnEWNZZ1Qmpa4MCiphaGKN9qkgewZb9bx2z4Gg85bKCCMsk4jyMsQZrPL88EY5j0IioKvtLGzHL-7bXHwrwjk3U0WrggJVUAQVFDyC3fU3py27xl-l972W1pKeGTsMoL0Unb0U_7KXCHZWOi46d22KNG-p95iK4PV6Gh3Nq0DXbn4WZBAa-XPhCLZbk1ivhCnMDDF3jUBtGMvGUjdn6tk0kHlj-o3GStMI3q7s6se6_rwXL_7HXryE-6l3COr72-zA1nJx5l7BXXu-nDWLHtyWExmeqgd39gej8cde8LKeL5Ad--fVAGfGH47HX64BwhckOg
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFAQX3g9DgUWCU7Fqe9fr9QGh0NI2qhNFIkithGR21xsSCZwQp6X5U_xGZv1IFB699cDJkj221t5vZr7xzs4AvPQYuinNmRt6nnYZp8ZV6HVcX8QK2XkQiayc6STq9cTxcdzfgJ_NXhibVtnYxNJQZxNt_5HvBHFVHY2Kt9Pvru0aZVdXmxYaFSyOzOIHhmzFm84ezu-rINh_P9g9dOuuAq4OmT93jTaMDaXkPPIkkhnjy2HkS18hk0C489g3GmmHNkqEUSSHCgUFV76nlbTREcXnXoFNZsHegs1-p9s_Wf3V4ZRhEFXvzvGo2CnQQ9oMyoC6qEAY-bE1D1g2Cvgbu_0zSfO3ldrSAe7f-t8-3W24WVNt0q504w5smPwuXKuaby7uwaeu3XilR4tvKDQ5k6iJOdFWCWbELmcUZFqmKhqyuye2yaA8Scz5yFZKQjSTusURHg1JDtrJB-om7QNK5Pm4uA8fL-XVHkArn-TmERC0cplQXHFNI6TDIRIyOrSF9JUwlq454Dfzn-q6ELvtB_I1LRMCqEgrzKSImbTETMoc2F7eM63KkFwo_c7CailpS4iXJyazL2ltkdIgk6GIAhZ5mUJOHIuhx40Xa2lCwTM7zK0GTWlt14p0BSUHXiwvo0WyUyBzMzktZZBD2gV0Bx5WGF6OhAoMoTHId0CsoXttqOtX8vGorHruIxnm1A8ceN0owmpc__4Wjy9-jedw_XDQTdKk0zt6AjcCq6e-bfezBa357NQ8hav6bD4uZs9qVSfw-bJV5BewTomY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDiZe-P4IDDASPI1ocZw4zgNCZaWjWldVYkhDQgqO46yVIC1NN9Z_jb-Os5O0Kh972wNPkZJL5MS_u_tdfL4DeOEF6KYUD9zQ85QbcKbdFL2OS0WcIjv3I5HZme5Hg4E4Po6HG_Cz2Qtj0iobm2gNdTZR5h_5rh9X1dGY2M3rtIhhp_tm-t01HaTMSmvTTqOCyIFe_MDwrXzd6-Bcv_T97rujvfdu3WHAVWFA565WOghyKTmPPInERlOZR1TSFFkFQp_HVCukIEqnIowimacoKHhKPZVKEykxfO4V2ERKHvgt2Bz2DoefVn94OAswoKp36ng48BK9pcmm9JmLyoRRYLDmDW3TgL8x3T8TNn9btbXOsHvzf_6Mt-BGTcFJu9KZ27ChiztwrWrKubgLnw_Nhiw1WnxDocmZRA0tiDLKMSNmmaMkU5vCqMleR-yQI3uS6PORqaCEKCd16yM8atLfb_c_MLff3mdEno_Le_DxUl7tPrSKSaEfAkHrl4mUp1yxCGlyiESN5abAfiq0oXEO0AYLiaoLtJs-IV8TmyjARFLhJ0H8JBY_SeDAzvKeaVWe5ELptwZiS0lTWtyemMxOktpSJX4mQxH5QeRlKXLlWOQe116spA4Fz8wwtxtkJbW9K5MVrBx4vryMlspMgSz05NTKILc0C-sOPKjwvBwJExhaY_DvgFhD-tpQ168U45Gthk6RJHNGfQdeNUqxGte_v8Wji1_jGWyhXiT93uDgMVz3jcpS0wVoG1rz2al-AlfV2Xxczp7WWk_gy2VryC_z65JY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesenchymal+ovarian+cancer+cells+promote+CD8%2B+T+cell+exhaustion+through+the+LGALS3-LAG3+axis&rft.jtitle=NPJ+systems+biology+and+applications&rft.au=Yakubovich%2C+Edward&rft.au=Cook%2C+David+P.&rft.au=Rodriguez%2C+Galaxia+M.&rft.au=Vanderhyden%2C+Barbara+C.&rft.date=2023-12-12&rft.issn=2056-7189&rft.eissn=2056-7189&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1038%2Fs41540-023-00322-4&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41540_023_00322_4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-7189&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-7189&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-7189&client=summon